China Powers Into Precision Medicine
This article was originally published in The Gray Sheet
Metastatic tumors, diabetes, cardiovascular and rare diseases are among the areas being targeted in China’s new precision medicine initiative in a bet that could be worth $10 billion by 2030.
You may also be interested in...
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.